INDV Indivior Pharmaceuticals Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Indivior Pharmaceuticals Inc reported revenue of $343M (up 13.6% from a year earlier), net income of $122M and diluted EPS of $0.98; over the last four quarters revenue was $1.33B and net income $356M; for the fiscal year ended December 2025 revenue was $1.24B, up 4.3% on the year before.
INDV annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.24B, gross profit $994M, operating income $262M, net income $210M (margin 16.9%), EPS $1.64
- Fiscal year ended Dec 2024: revenue $1.19B, gross profit $957M, operating income $38.0M, net income $7.00M (margin 0.6%), EPS $0.05
- Fiscal year ended Dec 2023: revenue $1.09B, gross profit $919M, operating income −$152M, net income −$126M (margin -11.5%), EPS −$0.92
- Fiscal year ended Dec 2022: revenue $901M, gross profit $749M, operating income −$77.0M, net income −$42.0M (margin -4.7%), EPS −$0.30
INDV quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $343M (up 13.6% year over year), net income $122M, EPS $0.98
- Quarter ended Mar 31, 2026: revenue $317M (up 19.2% year over year), net income $89.0M, EPS $0.69
- Quarter ended Dec 31, 2025 (from the annual report): revenue $357M (up 19.8% year over year), net income $103M, EPS $0.79
- Quarter ended Sep 30, 2025: revenue $314M (up 2.3% year over year), net income $42.0M, EPS $0.33
- Quarter ended Jun 30, 2025: revenue $302M (up 1.0% year over year), net income $18.0M, EPS $0.14
- Quarter ended Mar 31, 2025: revenue $266M (down 6.3% year over year), net income $47.0M, EPS $0.38
- Quarter ended Dec 31, 2024 (from the annual report): revenue $298M, net income $21.0M, EPS $0.16
- Quarter ended Sep 30, 2024: revenue $307M, net income $22.0M, EPS $0.16
- Quarter ended Jun 30, 2024: revenue $299M, net income −$97.0M, EPS −$0.72
- Quarter ended Mar 31, 2024: revenue $284M, net income $61.0M, EPS $0.45
INDV cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$27.0M, share buybacks $11.0M
- Fiscal year ended Dec 2024: operating cash flow $36.0M, share buybacks $173M
- Fiscal year ended Dec 2023: operating cash flow −$300M, share buybacks $33.0M
- Fiscal year ended Dec 2022: operating cash flow −$4.00M, share buybacks $90.0M
INDV balance sheet
- Jun 30, 2026: cash $222M, total assets $1.23B, total liabilities $1.44B, shareholders' equity −$208M, long-term debt $487M
- Mar 31, 2026: cash $175M, total assets $1.20B, total liabilities $1.34B, shareholders' equity −$144M, long-term debt $486M
- Dec 31, 2025: cash $195M, total assets $1.20B, total liabilities $1.30B, shareholders' equity −$98.0M, long-term debt $290M
- Sep 30, 2025: cash $445M, total assets $1.42B, total liabilities $1.62B, shareholders' equity −$207M, long-term debt $304M
- Jun 30, 2025: cash $510M, total assets $1.45B, total liabilities $1.71B, shareholders' equity −$257M, long-term debt $308M
- Mar 31, 2025: cash $372M, total assets $1.38B, total liabilities $1.66B, shareholders' equity −$285M, long-term debt $311M
- Dec 31, 2024: cash $319M, total assets $1.32B, total liabilities $1.65B, shareholders' equity −$337M, long-term debt $315M
- Dec 31, 2023: cash $316M, total assets $1.76B, total liabilities $1.94B, shareholders' equity −$184M, long-term debt $237M
What is INDV's revenue?
Indivior Pharmaceuticals Inc reported $1.33B of revenue over its last four quarters, through June 30, 2026.
Is INDV profitable?
Yes. Indivior Pharmaceuticals Inc earned $356M over the last four quarters.
What is INDV's EPS?
Diluted earnings per share over the last four quarters were $2.79; $0.98 in the latest quarter.